GF Fund Management’s Janux Therapeutics JANX Stock Holding History

GF Fund Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.8K	Sell	1,289 -53	-4%	-$768	﹤0.01%	481
2026 Q1	$18.7K	Buy	1,342 +161	+14%	+$2.21K	﹤0.01%	507
2025 Q4	$16.3K	Sell	1,181 -112	-9%	-$2.63K	﹤0.01%	529
2025 Q3	$31.6K	Sell	1,293 -50	-4%	-$1.22K	﹤0.01%	437
2025 Q2	$31K	Hold	1,343	–	–	﹤0.01%	458
2025 Q1	$36.3K	Buy	1,343 +241	+22%	+$9.08K	﹤0.01%	445
2024 Q4	$59K	Buy	+1,102	New	+$58.3K	﹤0.01%	373

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

GF Fund Management's JANX Position: Q2 2026 in Review

GF Fund Management reduced its Janux Therapeutics (JANX) stake by 3.9% in Q2 2026, selling an estimated $768 and leaving 1,289 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #481.

GF Fund Management first reported a position in JANX in Q4 2024 and has held it in 7 quarters since. The position peaked at $59K in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

GF Fund Management held 1,289 shares of Janux Therapeutics worth $19.8K as of Q2 2026.
GF Fund Management sold 53 Janux Therapeutics shares in Q2 2026, an estimated $768.
Janux Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #481 holding.
GF Fund Management first reported a position in Janux Therapeutics in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Janux Therapeutics position peaked at $59K in Q4 2024.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.